5 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | May 24, 2013 4:00 pm

The grades of five Pharmaceutical stocks are on the rise this week on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Alimera Sciences (NASDAQ:ALIM[2]) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Alimera Sciences engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The stock price has risen 46.4% over the past month, better than the 5.1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ALIM stock[3].

Johnson & Johnson (NYSE:JNJ[4]) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock[5].

Bristol-Myers Squibb (NYSE:BMY[6]) shows solid improvement this week. The company’s rating rises from a C to a B. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 15.2% over the past month. For more information, get Portfolio Grader’s complete analysis of BMY stock[7].

Watson Pharmaceuticals’ (NYSE:WPI[8]) ratings are looking better this week, moving up to an A from last week’s B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[9].

This is a strong week for Repros Therapeutics (NASDAQ:RPRX[10]). The company’s rating climbs to A from the previous week’s B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock[11].

Louis Navellier’s proprietary Portfolio Grader[12] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[13].

Source URL: https://investorplace.com/2013/05/5-pharmaceutical-stocks-to-buy-now-alim-jnj-bmy/

---